Sonovum GmbH
At Sonovum GmbH, we develop medical devices for non-invasive condition monitoring of the brain, especially for acute care. For the ultrasound recordings of a brain pulse curve, the CE mark for a class IIa product according to MDD has been available since summer 2020. With this biosignal, we serve different research fields of classification and monitoring of neurological conditions.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Monitoring
- Market Focus:
- Internationally (various countries)
Welcome
We are revolutionizing decision-making in clinical acute and critical care medicine
Based on our biosignals and the integration of clinical vital parameters, we carry out multimodal evaluations that were not previously possible. We generate our unique non-invasive biosignal, the brain pulse curve, using transcranial ultrasound and record physiological states and changes in the brain faster, earlier and more easily than current gold standards.
Our unique biosignal
Unique and new: the brain pulse curve opens up fundamentally new possibilities in diagnostics and monitoring for clinical users. With the decision support provided by our biosignal, we are initiating a fundamental change. This results in completely new examination procedures in the acute area and also in neurodegenerative diseases.
Multimodal evaluation
The recording of intracranial compliance is currently undergoing clinical trials. We are developing further application possibilities through knowledge-based multimodal evaluations in the coming years.
Interdisciplinary competence
Our team is characterized by the expertise in the field of biosignals, neurology and neurosurgery, data analysis as well as regulatory and clinical affairs
About Us
Integration into clinical workflows
We are currently completing a preliminary clinical study to monitor intracranial compliance to rule out the presence of critical intracranial pressure or reduced compliance. The clinical trial to obtain the CE mark for a class IIb product according to MDR will start in Q4 2022. The market launch is planned for the end of 2023.